FLT3-ITD-specific MRD assessment useful for clinical management of AML Presented ByProf. Alexander Perl, University of Pennsylvania, PA, USA TrialPhase 3, QuANTUM-First ConferenceASH 2023 7 February, 2024 15:05
MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML Presented ByDr Jad Othman, Royal North Shore Hospital, Australia ConferenceASH 2023 7 February, 2024 15:04
Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML Presented ByDr Musa Yilmaz, MD Anderson Cancer Center, TX, USA TrialPhase 1/2 ConferenceASH 2023 7 February, 2024 15:04
AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia Presented ByDr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA TrialPhase 2, AUGMENT-101 ConferenceASH 2023 7 February, 2024 15:04
Blinatumomab reduces toxicity in the consolidation phase in paediatric high-risk B-cell ALL Presented ByProf. Martin Schrappe, Hong Kong College of Paediatricians, China TrialPhase 3, AIEOP-BFM ALL 2017 ConferenceASH 2023 7 February, 2024 15:02
Promising results for olverembatinib in combination with venetoclax for Ph+ ALL Presented ByDr Xiaoyuan Gong, Chinese Academy of Medical Sciences, China TrialPhase 2 ConferenceASH 2023 7 February, 2024 15:02
Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants Presented ByDr Moritz Fürstenau, University of Cologne, Germany TrialPhase 2, CLL2-BAAG ConferenceASH 2023 7 February, 2024 15:01
Meet the Trialist: Prof. Jeff Sharman on ELEVATE-TN ExpertProf. Jeff Sharman , The US Oncology Network and Willamette Valley Cancer Institute, Oregon, USA TrialPhase 3, ELEVATE-TN ConferenceASH 2023 18 December, 2023 18:14
What every doctor should know about CLL in today’s treatment landscape ExpertDr Jennifer Brown, Dana-Farber Cancer Institute & Harvard University, MA, USA 21 August, 2023 14:58
QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD Presented ByDr Richard Schlenk, University of Heidelberg, Germany TrialPhase 3, QuANTUM-First ConferenceEHA 2023 2 August, 2023 16:54
MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib Presented ByDr Mark Levis, Johns Hopkins Hospital, Maryland, USA TrialMORPHO ConferenceEHA 2023 2 August, 2023 16:45
Long-term success for CD19 CAR T-cell therapy in CLL Presented ByDr Emily Liang, University of Washington, WA, USA TrialPhase 2 ConferenceEBMT 2023 15 June, 2023 17:31
Next-generation cell therapies for cancer: CAR-NK cells Presented ByDr Katy Rezvani, MD Anderson Cancer Center, TX, USA ConferenceEBMT 2023 15 June, 2023 17:20
Quizartinib plus chemotherapy improves OS in patients with AML undergoing ASCT Presented ByProf. Radovan Vrhovac, University Hospital Centre Zagreb, Croatia TrialPhase 3, QuANTUM-First ConferenceEMBT 2023 14 June, 2023 20:07
Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT Presented ByDr Ayman Sayyed, University of Toronto, Canada ConferenceEBMT 2023 14 June, 2023 20:02
Is ASCT a reasonable option in patients with invasive aspergillosis? Presented ByProf. Olaf Penack, Charité University Hospital of Berlin, Germany ConferenceEBMT 2023 14 June, 2023 19:55
Tacrolimus versus cyclosporine A in AML Presented ByDr Gesine Bug, Goethe University Frankfurt, Germany ConferenceEBMT 2023 14 June, 2023 19:48
Promising novel target identified for AML Presented ByProf. Edmund Waller, Emory University, GA, USA ConferenceEBMT 2023 14 June, 2023 19:42
Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL Presented ByProf. Jennifer Brown, Dana Farber Cancer Institute, MA, USA TrialPhase 3, ALPINE ConferenceASH 2022 20 February, 2023 11:40
Ibrutinib plus venetoclax displays long-term benefits in CLL Presented ByProf. John Allan, Weill Cornell Medicine, NY, USA TrialPhase 2, CAPTIVATE ConferenceASH 2022 20 February, 2023 11:28
Excellent results for triplet regimen in FLT3-mutated AML Presented ByProf. Nicholas Short, University of Texas, TX, USA ConferenceASH 2022 20 February, 2023 11:25
MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML Presented ByMr Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK ConferenceASH 2022 20 February, 2023 11:20
Promising results for triplet therapy with magrolimab in AML Presented ByProf. Naval Daver, Anderson Cancer Center, TX, USA TrialPhase 3, ENHANCE-3 ConferenceASH 2022 20 February, 2023 11:17
Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML? Presented ByProf. Matthias Stelljes, University of Muenster, Germany TrialPhase 3, EATL3-ASAP ConferenceASH 2022 20 February, 2023 11:13
Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL Presented ByProf. Mark Litzow, Mayo Clinic, MN, USA TrialPhase 3, ECOG-ACRIN-E1910 NCTN ConferenceASH 2022 20 February, 2023 11:07
High-dose methotrexate or standard interim maintenance in young patients with ALL? Presented ByMs Amy Kirkwood, University College London, UK TrialUKALL 2011 ConferenceASH 2022 20 February, 2023 11:01
Real world outcomes show ibrutinib delays need for next treatment longer than acalabrutinib in first-line CLL Presented ByDr Ryan Jacobs, Atrium Health Levine Cancer Institute, Charlotte, NC ConferenceASH 2022 28 December, 2022 22:42
Should we use intensive chemotherapy prior to allo-HCT in rel/ref AML? Presented ByProf. Matthias Stelljes, University of Muenster, Germany TrialPhase 3, ASAP ConferenceASH 2022 28 December, 2022 22:22
Pan-clonal score predicts first-line treatment response in AML Presented ByDr Yannik Severin, ETH Zurich, Switzerland ConferenceEHA 2022 1 July, 2022 11:54
Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML Presented ByDr Harry Erba, Duke Cancer Institute, NC, USA TrialPhase 3, QuANTUM-First ConferenceEHA 2022 1 July, 2022 11:52
No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics Presented ByProf. Nigel Russell, Guy's and St Thomas' NHS Foundation Trust, UK TrialPhase 3, AML19 ConferenceEHA 2022 1 July, 2022 11:49
New subtypes of oncogenic deregulation in childhood T-ALL Presented ByDr Petri Pölönen, St. Jude Children's Research Hospital, TN, USA ConferenceEHA 2022 1 July, 2022 11:45
Triple-therapy improves PFS in fit, previously untreated CLL Presented ByProf. Barbara Eichhorst, University Hospital Cologne, Germany TrialPhase 3, GAIA/CLL13 ConferenceEHA 2022 1 July, 2022 11:43
Blood cancer patients show strong T-cell response to COVID vaccines ConferenceASCO 2022 7 June, 2022 19:23
Young leukemia survivors face higher-than-average mortality rates for decades JournalCancer Epidemiology 25 May, 2022 22:55
Inhibiting the LSD1 enzyme renders some leukemia cells sensitive to TKI treatment JournalScience Signaling 25 April, 2022 19:24
Adding ivosidenib to azacitidine improves survival in IDH1-mutated AML JournalThe New England Journal of Medicine 20 April, 2022 23:00
Newly characterized mutation may define a novel leukemia subtype in kids JournalBlood Cancer Discovery 23 February, 2022 15:59
New Interfant protocol includes blinatumomab for KMT2A-r ALL Presented ByDr Inge van der Sluis, Princess Máxima Center for Pediatric Oncology, the Netherlands ConferenceASH 2021 4 February, 2022 12:00
Persistent disparities in ALL health outcomes Presented ByDr Sumit Gupta, University of Toronto, Canada TrialCOG ALL ConferenceASH 2021 4 February, 2022 11:59
EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL Presented ByProf. Patrice Chevallier, Nantes University Hospital, France TrialPhase 2, EWALL-INO ConferenceASH 2021 4 February, 2022 11:57
UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL Presented ByDr Sujith Samarasinghe, Great Ormond Street Hospital, UK TrialUKALL 2003 ConferenceASH 2021 4 February, 2022 11:55
AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML Presented ByDr Hartmut Döhner, Universitätsklinikum Ulm, Germany TrialPhase 2, AMLSG 16-10 ConferenceASH 2021 4 February, 2022 11:53
Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients Presented ByDr Justin Grenet, Weill Cornell Medical Center, NY, USA ConferenceASH 2021 4 February, 2022 11:51
Promising frontline triplet regimen for TP53-mutated AML Presented ByDr Naval Daver, MD Anderson Cancer Center, TX, USA TrialPhase 1/2 ConferenceASH 2021 4 February, 2022 11:49
Encouraging results of novel triplet combination for AML Presented ByDr Patrick Reville, MD Anderson Cancer Center, TX, USA TrialPhase 2 ConferenceASH 2021 4 February, 2022 11:48
Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen Presented ByDr Musa Yilmaz, MD Anderson Cancer Center, TX, USA ConferenceASH 2021 4 February, 2022 11:46
Benefits of eprenetapopt plus azacitidine for TP53-mutant MDS and oligoblastic AML Presented ByDr David Sallman, H. Lee Moffitt Cancer Center, FL, USA TrialPhase 2 ConferenceASH 2021 4 February, 2022 11:44
Improved risk stratification in MDS via gene-based scoring system Presented ByDr Elsa Bernard, Memorial Sloan Kettering Cancer Center, NY, USA ConferenceASH 2021 4 February, 2022 11:43
CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL Presented ByDr Paolo Ghia, Università Vita-Salute San Raffaele, Italy TrialPhase 2, CAPTIVATE ConferenceASH 2021 4 February, 2022 11:41
SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL Presented ByProf. Constantine Tam, Peter MacCallum Cancer Centre, Australia TrialPhase 3, SEQUOIA ConferenceASH 2021 4 February, 2022 11:39
Investigational therapies superior to standard-of-care in double-exposed CLL Presented ByDr Meghan Thompson, Memorial Sloan Cancer Center, NY, USA ConferenceASH 2021 4 February, 2022 11:36
Mechanisms behind TP53 mutations revealed in myeloproliferative neoplasms Presented ByDr Alba Rodriguez-Meira, University of Oxford, UK ConferenceASH 2021 4 February, 2022 10:51
Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL ExpertDr Jennifer Woyach, Ohio State University, OH, USA TrialPhase 3, Alliance A041202 ConferenceASH 2021 3 February, 2022 23:22
Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL ExpertDr. Talha Munir, Leeds Teaching Hospitals NHS Trust, UK TrialPhase 3, GLOW ConferenceASH 2021 3 February, 2022 23:15
CAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL ExpertProf. Paolo Ghia, Università Vita-Salute San Raffaele, Italy TrialPhase 2, CAPTIVATE ConferenceASH 2021 20 January, 2022 16:29
ASH 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceASH 2021 4 January, 2022 08:00
Novel immunotherapy for cancer takes cue from transplant rejection JournalNature Biotechnology 15 December, 2021 22:03
Some young people who undergo HCT retain ability to conceive JournalHuman Reproduction 20 October, 2021 19:04
Limited evidence supports many hematopoietic stem cell transplant guidelines JournalJAMA Network Open 19 October, 2021 23:16
Acalabrutinib on par with ibrutinib, easier to tolerate in advanced CLL JournalJournal of Clinical Oncology 17 August, 2021 17:47
Olutasidenib demonstrates efficacy in patients with relapsed/refractory IDH1 mutant AML Presented ByDr Stéphane de Botton , Institute Gustave Roussy, France TrialPhase 2, 2102M 101 ConferenceASCO 2021 12 August, 2021 23:20
Acalabrutinib as effective but better tolerated than ibrutinib in CLL Presented ByProf. John Byrd, Ohio State University Comprehensive Cancer Center, OH, USA TrialPhase 3, ELEVATE-RR ConferenceASCO 2021 12 August, 2021 13:22
Stop vincristine-dexamethasone pulse therapy in low-risk childhood ALL after one year: trial JournalThe Lancet Oncology 9 August, 2021 16:18
ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety compared with ibrutinib Presented ByDr. John Byrd , Ohio State University College of Medicine, USA TrialPhase 3, ELEVATE-RR JournalPhysician's Weekly ConferenceASCO 2021 6 August, 2021 11:55
ELEVATE-TN: Long-term efficacy in chronic lymphocytic leukemia Presented ByDr. John Byrd, Ohio State University College of Medicine, USA TrialPhase 3, ELEVATE-TN JournalPhysician's Weekly ConferenceASCO 2021 6 August, 2021 11:20
Sabatolimab achieved durable responses in patients with high-risk MDS and AML Presented ByProf. Andrew Wei, Alfred Hospital and Monash University, Australia ConferenceEHA 2021 5 August, 2021 14:27
Final analysis of EURO-SKI: primary endpoints met in chronic myeloid leukaemia Presented ByProf. Susanne Saußele, Heidelberg University, Germany TrialEURO-SKI ConferenceEHA 2021 5 August, 2021 14:13
Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL Presented ByProf. Peter Hillmen, University of Leeds, UK TrialPhase 3, ALPINE ConferenceEHA 2021 5 August, 2021 14:08
Oral azacitidine improves overall survival in patients with acute myeloid leukaemia Presented ByProf. Hartmut Döhner, Universitätsklinikum Ulm, Germany TrialPhase 2, QUAZAR AML-001 ConferenceEHA 2021 5 August, 2021 13:59
Reduced-intensity conditioning ASCT is effective in older patients with AML Presented ByProf. Nigel Russell, Guy's Hospital, UK TrialAML16; AML18 ConferenceEHA 2021 5 August, 2021 13:55
ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia Presented ByDr Jeff Sharman, US Oncology Network, USA TrialPhase 3, ELEVATE-TN ConferenceEHA 2021 5 August, 2021 13:50
ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib Presented ByProf. Peter Hillmen, St James’s University Hospital, UK TrialPhase 3, ELEVATE-RR ConferenceEHA 2021 5 August, 2021 13:43
Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL Presented ByDr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands TrialPhase 2, HOVON 139/GiVe ConferenceEHA 2021 5 August, 2021 13:38
GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment Presented ByProf. Arnon Kater, Amsterdam University Medical Centres, the Netherlands TrialPhase 2, GLOW ConferenceEHA 2021 5 August, 2021 13:33
Protein profiles may predict stable, progressive chronic lymphocytic leukemia JournalJournal of Leukocyte Biology 30 July, 2021 21:39
Survival outcomes improving for certain adolescent and young adult cancers JournalCancer 26 July, 2021 23:33
Ficlatuzumab plus chemo shows early promise in refractory AML JournalBlood Cancer Discovery 20 July, 2021 16:24
Whole-genome sequencing identifies more gene defects in patients with blood cancer JournalThe New England Journal of Medicine 10 March, 2021 23:00
More complicated course of COVID-19 in leukaemia patients Presented ByDr Susanne Ghandili, University Medical Center Hamburg-Eppendorf, Germany ConferenceASH 2020 18 February, 2021 09:34
Older age and imatinib treatment associated with COVID-19 mortality in CML Presented ByDr Delphine Rea, Université de Paris, France TrialCANDID ConferenceASH 2020 18 February, 2021 09:32
Improved outcomes, but still substantial part experiences relapses Presented ByDr Danielle Fredman, Sheba Medical Center, Israel ConferenceASH 2020 18 February, 2021 09:26
Strong correlation between peripheral blood and bone marrow NGS MRD Presented ByDr Lori Muffly, Stanford University, California, USA ConferenceASH 2020 18 February, 2021 09:24
Encouraging outcomes after autoHCT in patients with ALL Presented ByProf. Sebastian Giebel, Maria Skłodowska-Curie National Research Institute of Oncology, Poland ConferenceASH 2020 18 February, 2021 09:23
Prognostic validity of AML composite model in predicting mortality Presented ByDr Shannon Murphy, Dalhousie University, Canada ConferenceASH 2020 18 February, 2021 09:21
Venetoclax plus hypomethylating agents in favourable-risk AML Presented ByDr Shukaib Arslan, City Of Hope Helford Clinical Research Hospital, California, USA ConferenceASH 2020 18 February, 2021 09:19
Encouraging clinical activity of decitabine plus ipilimumab in R/R or secondary MDS/AML Presented ByMs Jacqueline S. Garcia, Dana-Farber Institute, Massachusetts, USA ConferenceASH 2020 18 February, 2021 09:18
Bosutinib effective and well tolerated in newly diagnosed CP-CML Presented ByProf. Tim Brümmendorf, RWTH Aachen University, Germany TrialPhase 3, BFORE ConferenceASH 2020 18 February, 2021 09:17
AML patients with specific mutations are unlikely to achieve MRD Presented ByDr Maximilian Stahl, Memorial Sloan Kettering Cancer Center, New York, USA ConferenceASH 2020 18 February, 2021 09:15
Comparable outcomes with gilteritinib or quizartinib in R/R AML Presented ByDr Alexander Perl, University of Pennsylvania, USA TrialPhase 3, QuANTUM-R ConferenceASH 2020 18 February, 2021 09:14
First-in-class macrophage immune checkpoint inhibitor in AML Presented ByDr David Sallman, H. Lee Moffitt Cancer Center and Research Institute, Florida, USA TrialPhase 1 ConferenceASH 2020 18 February, 2021 09:11
Bispecific DART® as salvage therapy for primary induction failure and early relapse Presented ByDr Ibrahim Aldoss, City of Hope Medical Center, California, USA TrialPhase 1/2 ConferenceASH 2020 18 February, 2021 09:09
Efficacy and safety of ponatinib in patients with CP-CML who failed second-generation TKIs Presented ByDr Hagop Kantarjian, MD Anderson Cancer Center, Texas, USA TrialOPTIC, PACE ConferenceASH 2020 18 February, 2021 09:08
Gilteritinib in R/R AML patients priorly treated with midostaurin or sorafenib Presented ByDr Alexander Perl, University of Pennsylvania, USA TrialCHRYSALIS, ADMIRAL ConferenceASH 2020 18 February, 2021 09:07
Addition of venetoclax provides an effective, lower-intensity regimen Presented ByDr Tapan Kadia, MD Anderson Cancer Center, Texas, USA ConferenceASH 2020 18 February, 2021 09:05
First-in-class STAMP inhibitor versus bosutinib in resistant or intolerant CML Presented ByDr Andreas Hochhaus, Universitätsklinikum Jena, Germany TrialPhase 3, ASCEMBL ConferenceASH 2020 18 February, 2021 08:58
PFS and ORR benefits of first-line ibrutinib-based treatment in CLL Presented ByProf. Jan Burger, MD Anderson Cancer Center, Texas, USA TrialPhase 3, RESONATE-2, iLLUMINATE ConferenceASH 2020 18 February, 2021 08:54
PARP inhibitors linked to myelodysplastic syndrome, AML, meta-analysis confirms JournalThe Lancet Haematology 12 January, 2021 16:14
Origins of blood cancer traced to early childhood, decades before diagnosis ConferenceAmerican Society of Hematology 2020 Annual Meeting 17 December, 2020 17:42
Tyrosine kinase inhibitor discontinuation can improve CML outcomes JournalJAMA Oncology 25 November, 2020 21:36
New guideline helps patients and parents navigate pediatric acute lymphoblastic leukemia JournalNational Comprehensive Cancer Network 7 October, 2020 21:24
OS benefit in VIALE-C trial Presented ByProf. Andrew Wei, Monash University, Australia TrialPhase 3, VIALE-C ConferenceEHA 2020 9 September, 2020 13:22
DEC10-VEN superior to intensive chemotherapy in high-risk AML Presented ByDr Abhishek Maiti, University of Texas MD Anderson Cancer Centre, USA TrialPhase 2 ConferenceEHA 2020 9 September, 2020 13:18
Magrolimab plus azacitidine: good ORR in MDS/AML Presented ByProf. Naval Draver, University of Texas MD Anderson Cancer Centre, USA TrialPhase 1 ConferenceEHA 2020 9 September, 2020 13:14
Asciminib monotherapy in Ph+ CML: major molecular responses Presented ByProf. Timothy Hughes, University of Adelaide, Australia TrialPhase 1 ConferenceEHA 2020 9 September, 2020 13:08
CML TKI interruption: Swedish registry results Presented ByDr Hjalmar Flygt, Uppsala University Hospital, Sweden ConferenceEHA 2020 9 September, 2020 13:03
Better outcomes adding enasidenib to azacitidine in mIDH2-AML Presented ByDr Courtney Di Nardo, MD Anderson Cancer Centre, USA TrialPhase 2, AG-221-AML-005 ConferenceEHA 2020 9 September, 2020 12:55
Two trials: acalabrutinib in CLL Presented ByProf. John Byrd, Ohio State University Comprehensive Cancer Centre, USA TrialPhase 2, ACE-CL-001, ASCEND ConferenceEHA 2020 9 September, 2020 12:19
Deep responses in R/R CLL with venetoclax monotherapy ExpertProf. Arnon Kater, Amsterdam University Medical Center, the Netherlands TrialPhase 3, VENICE 1 ConferenceEHA 2020 9 September, 2020 11:35
MRD assessment post-CAR-T predicts ALL allo-HSCT bridging ExpertDr Hui Wang, Hebei Yanda Ludaopei Hospital, China ConferenceEHA 2020 9 September, 2020 11:02
Higher risk of severe COVID-19 seen in people with blood cancers JournalThe Lancet Oncology 1 September, 2020 18:28
Venetoclax + navitoclax promising for R/R ALL or LL Presented ByProf. Elias Jabbour , University of Texas MS Anderson Cancer Centre, USA TrialPhase 1 ConferenceEHA 2020 28 August, 2020 12:23
Microbiome predicts B-ALL predisposition Presented ByDr Carolina Vincente-Dueñas, Institute of Biomedical Research of Salamanca, Spain ConferenceEHA 2020 28 August, 2020 12:15
Socioeconomic disparities and survival in paediatric AML Presented ByDr Lena Winestone, UCSF Benioff Children’s Hospital, USA TrialPhase 3, AAML0531 and AAML1031 ConferenceASH 2019 5 March, 2020 23:55
Likely new standard of care: Blinatumomab for children with relapsed B-ALL Presented ByProf. Patrick A. Brown, Johns Hopkins Kimmel Cancer Center, Baltimore, USA TrialPhase 3, AALL1331 ConferenceASH 2019 5 March, 2020 23:15
Oral azacitidine improves overall survival in patients with AML in remission Presented ByDr Andrew Wei, Alfred Hospital, Australia TrialPhase 3, QUAZAR AML-001 ConferenceASH 2019 5 March, 2020 21:39
Mild renal impairment in African Americans does not affect OS in AML Presented ByDr Abby Statler, Cleveland Clinic, USA ConferenceASH 2019 5 March, 2020 19:10
Anti-CD70 is safe with hypomethylating agents in AML Presented ByProf. Adrian Ochsenbein, Bern University Hospital, Switzerland ConferenceASH 2019 5 March, 2020 17:01
20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon Presented ByDr Maria Vazquez, MD Anderson Cancer Center, Houston, USA ConferenceASH 2019 5 March, 2020 16:26
MRD assessment to guide pre-emptive treatment decisions Presented ByProf. Uwe Platzbecker, University Hospital Carl Gustav Carus, Germany TrialPhase 2, RELAZA2 ConferenceASH 2019 5 March, 2020 16:04
Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT Presented ByDr Xiaowen Tang; Dr James Foran TrialPhase 2, ECOG-ACRIN E2906 ConferenceASH 2019 5 March, 2020 13:16
Residual disease in AML patients prior to stem cell transplant increases relapse risk Presented ByDr Christopher Hourigan, NIH, USA ConferenceEHA 2019 9 August, 2019 23:05
Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL Presented ByDr Eugen Tausch, University of Ulm, Germany TrialCLL14 ConferenceEHA 2019 9 August, 2019 22:38
Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML Presented ByDr Alexander Perl, University of Pennsylvania, USA TrialPhase 3, ADMIRAL ConferenceEHA 2019 9 August, 2019 22:14
CAR-T cell therapy in ALL as breakthrough advance Presented ByProf. Mohamad Mohty, Saint-Antoine Hospital and University Pierre & Marie Curie, France TrialPhase 2, ELIANA ConferenceEHA 2019 9 August, 2019 21:36
Initial data on AMV564 in patients with relapsed/refractory AML Presented ByProf. Gail Roboz, Weill Cornell Medicine, USA TrialPhase 1, AMV564-101 ConferenceEHA 2019 9 August, 2019 21:18
Exciting survival data for ibrutinib vs placebo in treatment-naïve, early-stage CLL Presented ByDr Petra Langerbeins, University of Cologne, Germany TrialPhase 3, CLL12 ConferenceEHA 2019 9 August, 2019 16:26
ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL Presented ByDr Paolo Ghia, Vita-Salute San Raffaele University, Italy TrialPhase 3, ASCEND ConferenceEHA 2019 9 August, 2019 15:28
Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia Presented ByProf. Jorge Cortes, University of Texas MD Anderson Cancer Center, USA TrialPhase 1 ConferenceEHA 2020 9 August, 2019 12:22
Guadecitabine vs treatment of choice in AML Presented ByProf. Pierre Fenaux, Hôpital Saint-Louis, France TrialPhase 3, ASTRAL-1 ConferenceEHA 2019 9 August, 2019 09:25
Venetoclax-obinutuzumab combination elicits high response rates in CLL Presented ByDr Kirsten Fischer, University of Cologne, Germany TrialPhase 3, CLL14 ConferenceEHA 2019 9 June, 2019 23:28